KIAA0701 inhibitors represent a class of chemical compounds designed to modulate the activity of the KIAA0701 protein, a protein that plays a crucial role in various cellular processes. KIAA0701 is associated with DNA damage repair, transcriptional regulation, and chromatin remodeling. By inhibiting the activity of KIAA0701, these inhibitors can alter the dynamics of gene expression and DNA repair pathways, potentially influencing cellular growth and differentiation. Structurally, KIAA0701 inhibitors are often characterized by a high affinity for the active or binding domains of the protein, making them specific in their action. These compounds often employ mechanisms that can disrupt the interaction of KIAA0701 with other proteins or DNA, leading to changes in the protein's function at the molecular level.
KIAA0701 inhibitors are of interest due to their ability to modulate cellular responses to stress and genomic instability. By targeting specific regions of KIAA0701, they can prevent the activation of certain pathways involved in the maintenance of genomic integrity. This disruption can impact the regulation of gene expression, particularly in response to damage signals. Additionally, research into KIAA0701 inhibitors focuses on optimizing their selectivity and minimizing off-target effects, ensuring that their activity is confined to the intended protein pathways. These inhibitors can be synthesized through various chemical processes, and ongoing studies often explore their structure-activity relationships to better understand how modifications to their chemical structures can enhance their potency or specificity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Inhibits cyclin-dependent kinases (CDKs) which are involved in the phosphorylation of UHRF1BP1L, thus reducing its activity. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Targets CDKs that regulate the cell cycle and phosphorylation status of UHRF1BP1L, leading to its functional inhibition. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Selectively inhibits CDKs and therefore decreases phosphorylation-dependent functions of UHRF1BP1L. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
CDK inhibitor that would prevent phosphorylation and subsequent activation of UHRF1BP1L. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
A potent CDK inhibitor which would impede the phosphorylation cycle necessary for UHRF1BP1L function. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $153.00 $464.00 | 20 | |
Inhibits adenosine kinase which could decrease phosphorylation levels indirectly affecting UHRF1BP1L activity. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
P38 MAP kinase inhibitor that may reduce UHRF1BP1L activity by altering stress response signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Another p38 MAP kinase inhibitor that could decrease the phosphorylation of UHRF1BP1L through stress pathway inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which is involved in signaling pathways that may phosphorylate and thereby regulate UHRF1BP1L. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
This p38 MAPK inhibitor could diminish the phosphorylation and activity of UHRF1BP1L by altering the MAPK pathway. | ||||||